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Abstract
Mitochondria are cellular organelles that orchestrate a vast range
of biological processes, from energy production and metabolism to
cell death and inflammation. Despite this seemingly symbiotic
relationship, mitochondria harbour within them a potent agonist
of innate immunity: their own genome. Release of mitochondrial
DNA into the cytoplasm and out into the extracellular milieu acti-
vates a plethora of different pattern recognition receptors and
innate immune responses, including cGAS-STING, TLR9 and
inflammasome formation leading to, among others, robust type I
interferon responses. In this Review, we discuss how mtDNA can
be released from the mitochondria, the various inflammatory
pathways triggered by mtDNA release and its myriad biological
consequences for health and disease.
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Introduction
Serving as a first line of defence, the innate immune system guards us
against a plethora of insults and invading microorganisms. Infection
by pathogenic agents is detected in cells by pattern recognition recep-
tors (PRRs) which recognise specific pathogen-associated molecular
patterns (PAMPs). PRRs can be broadly classified into four distinct
groups: NOD-like receptors (NLRs), Toll-like receptors (TLRs), reti-
noic acid-inducible gene-I (RIG-I)-like receptors (RLRs) and C-type
lectin receptors (CLRs) [1]. Upon detection of a PAMP, PRRs initiate a
multitude of different signalling pathways, which culminate in the
up-regulation of various type I interferons, pro-inflammatory
chemokines and cytokines. These prime the adaptive immune system
and create a hostile environment for the microorganism in which to
survive. Additionally, damage-associated molecular patterns
(DAMPs) are immune triggers that arise from the cell itself, such as
proteins or DNA, and can activate innate immune pathways [2].
Mitochondria first appeared in eukaryotic cells about two billion
years ago as a-proteobacterium, in what is thought to be an
endosymbiotic relationship [3,4]. Over time, these bacteria evolved
to become the much-studied organelle that we know today, playing
crucial roles in metabolism, calcium homeostasis and cell death.
Nevertheless, they have maintained an independent genome, which
encodes 37 genes, comprised of 13 mRNAs forming key components
of the oxidative phosphorylation system, in addition to 2 ribosomal
RNA components and 22 tRNAs [3,4]. An estimated 1,000 proteins
are located in the mitochondria, all of which, except those encoded
by mtDNA, are translated in the cytosol and imported into the mito-
chondria [5].
Mitochondrial DNA itself is a circular molecule of double-
stranded (ds)DNA. Transcription of both the heavy and light strand
results in long, full-length transcripts which are processed by RNase
enzymes to produce mature mRNA, tRNA and ribosomal RNA. In
mammals, the polymerase responsible for mtDNA replication is
DNA polymerase c, but as POLc cannot replicate dsDNA, the DNA
helicase Twinkle is required to act directly before to unwind the
DNA structure. Newly synthesised single-stranded (ss)DNA is
bound by mitochondrial single-stranded DNA-binding protein to
prevent secondary structure formation and attack by nucleases.
Mitochondrial DNA replication has recently been reviewed exten-
sively elsewhere [6]; here, we focus on the unique aspects of
mtDNA which make it immunostimulatory. We will then discuss
how mtDNA which is ejected from the mitochondria under specific
circumstances can activate different innate immune pathways,
including cGAS-STING signalling, inflammasomes and Toll-like
receptors. We will also focus on the role of mtDNA in the formation
of neutrophil extracellular traps (NETs) and the transfer of mtDNA
between cells.
Mitochondrial DNA as a stimulator of the immune system
Potentially stemming from its bacterial origin, mitochondrial DNA is
sensed as “foreign”, suggesting that it is seen differently to “self”
DNA in cells. One example of this can be seen in its methylation
status, where many studies have reported mtDNA to be hypomethy-
lated compared to nuclear DNA [7,8], despite the presence of DNA
methyltransferases in the mitochondria [9,10]. Some groups have
reported aberrant methylation patterns of mtDNA, including 5-
methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at CpG
motifs [9–14], although others have proposed technical limitations
to this work and using more sensitive techniques report that mtDNA
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is devoid of CpG methylation [15]. Clearly, more effort is required
in determining the precise degree of methylation in mtDNA, but if
studies showing an absence of CpG methylation are correct, then
mtDNA would harbour unmethylated CpG motifs similar to bacterial
DNA, which could potentially activate pattern recognition receptors
such as TLR9, absent in melanoma 2 (AIM2) and cGAS [15–18].
Mitochondrial DNA replication and transcription itself may repre-
sent a rich source of potential activators of DNA pattern recognition
receptors; for example, RNA:DNA hybrids form during transcrip-
tion, in addition to long stretches of ssDNA and R-loops composed
of RNA:DNA hybrids with a non-template ssDNA which can be
recognised by cGAS [16].
Mitochondrial DNA exists in the mitochondrial matrix in close
proximity to the electron transport chain, a major source of reac-
tive oxygen species. Due to this, it is particularly vulnerable to
oxidation, resulting in mtDNA mutations which can contribute to
the pathogenesis of cancer [17], diabetes [18] and ageing [19]. It
was thought the cell had limited capacity to repair mtDNA;
however, multiple repair pathways are now well characterised
[20]. Mitochondrial DNA is often schematically represented as a
plasmid structure; however, this is an over-simplification. Rather,
super-resolution imaging has revealed that it is densely compacted
into nucleoids consisting of one copy of mtDNA and a number of
different proteins [21], the most notable of which is mitochondrial
transcription factor A (mtTFA, commonly referred to as TFAM). It
might be assumed that the compaction of mtDNA into protein
structures shields DNA from recognition, but this is not the case
as we shall discuss further in this Review, and in fact, a number
of studies have shown that TFAM itself might be immunostimula-
tory [13,14].
In a landmark study in 2004, Collins et al [22] found that inject-
ing mtDNA into the joints of mice resulted in localised inflammation
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and arthritis. Further investigation revealed that the inflammation
was dependent on the presence of oxidatively damaged bases in the
mtDNA, as injection of an oligodeoxynucleotide (ODN) with the
same sequence but without the oxidised residue had no effect. The
observation that mtDNA can elicit potent immune responses opened
a whole new field of research, and it is now appreciated that mtDNA
can stimulate many PRRs, including cGAS, TLR9 and inflamma-
somes (Fig 1). Release of mtDNA from mitochondria and subse-
quent recognition by PRRs occurs during many cellular processes,
including infection, cell death and neurodegeneration, and this will
be the focus of the rest of this Review.
mtDNA-dependent activation of cGAS-STING signalling
mtDNA release in infection
Through necessity, cells have evolved elegant systems to detect the
presence of invading pathogenic DNA. Cyclic GMP-AMP synthase
(cGAS) is one such direct detector, which binds dsDNA to form a
dimer [23,24]. cGAS then undergoes a conformational change
which facilitates the conversion of ATP and GTP into 2030-cyclic
GMP-AMP (cGAMP) [25–31]. cGAMP is a second messenger, which
binds the endoplasmic reticulum (ER)-resident protein stimulator of
interferon genes (STING) inducing a conformational change in its
C-terminal tail. TANK-binding kinase 1 (TBK1) is recruited to
STING which phosphorylates it and the transcription factor inter-
feron regulatory factor 3 (IRF3), eliciting the transcription of
hundreds of interferon stimulatory genes (ISGs) that are potently
anti-viral [32] (Fig 2). cGAS was assumed to be primarily cytosolic
to avoid persistent activation by self-DNA in the nucleus, but recent
work has shown it to be present in the nucleus [33,34] and at the
plasma membrane [35]. A recent attempt to resolve these discrep-
ancies by Volkmann et al [36] reveals a more complex model than
the cytosolic DNA sensing paradigm. The authors show that the
majority of cGAS protein is nuclear, and they propose a model
where cGAS must be “desequestered” prior to its full activation.
However, it remains unclear how cytosolic DNA can be detected by
cGAS, if cGAS is tethered in the nuclear compartment. Three inde-
pendent studies were the first to show that mtDNA released from
mitochondria is able to activate cGAS-STING signalling [37–39].
White et al and Rongvaux et al explored mtDNA release in the
context of cell death (discussed later in this Review), whereas West
et al provided evidence that TFAM deficiency promotes mitochon-
drial stress and mis-packaged mtDNA, resulting in their ejection
into the cytoplasm where they bind and activate cGAS initiating a
type I interferon response [39] (Fig 2). Of pathophysiological rele-
vance, infection with Herpes simplex virus-1 (HSV-1) or vesicular
stomatitis virus (VSV) results in mtDNA stress, TFAM depletion
and mtDNA entrance into the cytoplasm. The cytoplasmic mtDNA
is then sensed by cGAS, triggering cGAS-STING signalling leading
to the up-regulation of a plethora of interferon genes, conferring an
anti-viral state on the cell. Importantly, Tfam+/ cells, which
exhibit mtDNA stress, are more resistant to infection with HSV-1 or
VSV than wild-type cells, as they have heightened ISG expression
owing to mtDNA release. Mechanistically, the HSV-1 virus encodes
a nuclease, UL12.5, which localises to the mitochondria and
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Figure 1. Overview of pro-inflammatory signalling pathways engaged by mitochondrial DNA.
Mitochondrial DNA (mtDNA) can trigger various pro-inflammatory signalling pathways by endosomal localised TLR9 or via cytosolic cGAS-STING or via cytosolic
inflammasome (AIM2 or NLRP3). Top: TLR9 binds mtDNA in the endosome eliciting an NF-jB-dependent pro-inflammatory signalling program. Middle: cGAS recognises
mtDNA in the cytosol and activates endoplasmic reticulum (ER)-localised STING triggering an interferon response. Bottom: mtDNA-dependent inflammasome activity leads
to caspase-1-dependent maturation or pro-inflammatory IL-1 and IL-8.
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degrades mtDNA, resulting in complete loss of mtDNA in infected
cells [40,41]. Removal of mtDNA in infected cells does not appear
to impact HSV replication [42]. Furthermore, exonuclease activity is
required for effective viral DNA production to maintain cell-to-cell
infectivity, though whether this is related to UL12.5’s mtDNA-
targeted nuclease activity is unknown [43].
Curiously, infection with RNA viruses, such as dengue virus, also
elicits a cGAS-STING response, despite cGAS being a DNA-specific
PRR [44]. Several studies have now shown that dengue virus causes
the release of predominantly oxidised mtDNA into the cytosol,
where it can activate both cGAS [45,46] and TLR9 [47]. Dengue
virus has evolved strategies to circumvent cytosolic mtDNA-induced
cGAS signalling during infection by encoding proteases which target
cGAS and STING for degradation, thus ensuring persistence of the
virus [46,48,49].
Infection with the bacterial pathogen Mycobacterium tuberculosis
triggers cGAS activation and subsequent IRF3-dependent type I
interferon response [50–52]. This was assumed to be solely due to
detection of mycobacterium DNA, but other studies have identified
a role for mitochondrial stress and ensuing release of mtDNA into
the cytoplasm [53]. This observation is strain-dependent but does
propose a role for mitochondrial stress and dynamics on the
M. tuberculosis-induced release of mtDNA. Previous work has
observed cytochrome c release from mitochondria in cells infected
with M. tuberculosis, indicating that there may be a possible role for
BAX/BAK-dependent mitochondrial permeabilisation (discussed in
detail later) in infection-related mtDNA release [54] (Fig 2).
Pathogen-infected cells often secrete IL-1b due to inflammasome
activation. A recent report by Aarreberg et al discovers a link
between IL-1b secretion in infected cells, which can then activate a
cGAS-STING-dependent type I interferon response in surrounding
bystander cells. Interestingly, IL-1b stimulation of bystander cells
increases mitochondrial mass, decreases mitochondrial membrane
potential and induces mtDNA release [55]. However, mtDNA
release is observed in the absence of detectable cytochrome c release
and cell death, suggesting that this is not the mechanism of mtDNA
release, although it does not rule out limited mitochondrial perme-
abilisation seen by us and others in the context of infection (see
below). This is not the first time IL-1R signalling has been impli-
cated in cell-intrinsic defence [56–58], but it is the first to suggest
that mtDNA release plays a key role in the initiation of cGAS-STING
signalling in the bystander cells.
mtDNA activation of cGAS-STING during cell death
During programmed cell death, the pro-apoptotic proteins BAX and
BAK permeabilise the mitochondrial outer membrane to allow the
passage of pro-apoptotic molecules to move from the inner
membrane space into the cytosol, where they can initiate a caspase
cascade, resulting in a rapid cell death [59]. White et al and Rong-
vaux et al showed that in the absence of apoptotic caspase activa-
tion, mtDNA activates cGAS in a promiscuous manner, which
in vivo leads to mildly elevated IFN-b protein levels in blood, though
a level sufficient to induce the expression of interferon-stimulated
genes [37,38] (Fig 3). This suggests that apoptotic caspases play a
crucial role in dampening type I interferon responses in dying cells,
maintaining the “immune-silent” nature of apoptosis (Fig 3).
Further work has shown that apoptotic caspases directly cleave
cGAS, IRF3 and mitochondrial anti-viral signalling protein (MAVS),
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Figure 2. mtDNA-dependent activation of cGAS-STING signalling.
Various mitochondrial stresses including bacterial or viral infection can lead to mtDNA release. Alternatively, activation of BAX and BAK leads to outer mitochondrial
membrane permeabilisation (MOMP) and mtDNA release. Once cytoplasmic, mtDNA can bind the DNA sensing protein cGAS that catalyses the production of the secondary
messenger 2030 cyclic GMP–AMP (2030cGAMP) from ATP and GTP. cGAMP binds the adaptor molecule STING on the ER leading to activation of TBK1 kinase. Active TBK1
phosphorylates the transcription factor IRF3 initiating a type I interferon response.
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key proteins required for the production of type I interferon [60],
supporting the notion that caspases dampen the immune response
during cell death. High-resolution imaging studies have further
expanded our understanding of how mtDNA is released from the
mitochondria during cell death. We and others recently showed that
BAX and BAK can permeabilise the mitochondrial outer membrane,
but in the context of caspase inhibition these pores grow dramati-
cally, sufficient to allow inner membrane herniation and extrusion
of mtDNA [61–63] (Fig 3). We found that under caspase-inhibited
conditions, mitochondrial permeabilisation leads to down-regulation
of inhibitor of apoptosis proteins (IAPs), NF-jB-inducing kinase
(NIK) activation and an NF-jB transcriptional program, in addition
to mtDNA release-induced cGAS-STING activation [64]. The cytoki-
nes and chemokines up-regulated via NF-jB after mitochondrial
permeabilisation can serve to promote macrophage activation
[64,65]. This leads to robust anti-tumour effects, highlighting a
potential therapeutic role for caspase inhibition in cancer treatment
[64]. Collectively, these results help to reconcile how predominantly
cytosolic cGAS can be activated by mtDNA during cell death. Never-
theless, a number of unresolved questions remain. Firstly, is inner
membrane permeabilisation a regulated process, and if so, how? A
rapid inner membrane permeabilisation of sufficient size to allow
the passage of small ions is observed minutes after outer membrane
permeabilisation [61], but is insufficient to allow mtDNA nucleoid
extrusion and is probably only transient, as inner membrane poten-
tial can be maintained after outer membrane permeabilisation [66–
69]. Secondly, there are cell type differences in the degree of inner
membrane permeabilisation, as different studies report varying
degrees of mtDNA release during cell death [61,62], implying that
specific cell-intrinsic factors play a role in inner membrane perme-
abilisation. Finally, the physiological relevance of cell death-related
mtDNA release is unknown. Most cell types undergo rapid and
complete caspase-dependent apoptosis in vivo, presumably limiting
any potential for mtDNA-driven inflammation during cell death.
However, some cell types, for instance cardiomyocytes, display defi-
cient caspase activity downstream of mitochondrial permeabilisa-
tion [70]. Such cells might generate a greater type I anti-viral
interferon response after mitochondrial permeabilisation. Alterna-
tively, cGAMP might transfer from apoptotic to healthy cells, serv-
ing as an “early warning” defence system, instructing healthy cells
to transcribe genes important for their survival (Fig 4) [71,72].
In addition to DNA, mitochondria also possess dsRNA which is
known to be potently immunogenic [73]. Mitochondrial dsRNA
arises from transcription of both the heavy and lights strands of
mtDNA; however, although the light strand is rapidly degraded the
heavy strand is not, and nearly all the dsRNA detected in the cyto-
plasm are of mitochondrial origin. The mitochondrial helicase SUV3
and polynucleotide phosphorylase PNPase dampen the accumula-
tion of dsRNA, but when these are depleted, dsRNA accumulates in
the cytoplasm where it activates a type I interferon response driven
by the dsRNA receptor MDA5 [74]. Silencing of BAX and BAK
suppresses the type I interferon response, strongly suggesting that
BAX/BAK-dependent mitochondrial outer membrane permeabilisa-
tion is responsible for mitochondrial dsRNA escape into the cyto-
plasm [74] Furthermore, patients with mutations leading to a
decrease in PNPT1, the gene that encodes PNPase protein, exhibit
greater accumulation of dsRNA and elevated interferon levels in
their serum [74].
Mitochondrial outer membrane permeabilisation is a rapid and
complete event, spreading to all mitochondria in a cell. Following
formation of BAX/BAK pores, pro-apoptotic proteins such as cyto-
chrome c are released from the intermembrane space where they
initiate the caspase cascade, culminating in cell death. However, we
have found that under conditions of sub-lethal stress, a limited
number of mitochondria in a cell can undergo permeabilisation,
called minority MOMP, leading to genomic instability and
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Figure 3. BAX/BAK-dependent initiation of inflammation.
Following a pro-apoptotic stress, BAX and BAK are activated leading to mitochondrial outer membrane permeabilisation. This enables the release of caspase-activating
proteins from the mitochondrial intermembrane space. Following this, macropores form on the mitochondrial outer membrane causing extrusion and permeabilisation of
the inner membrane. This enables release of mtDNA. Mitochondrial double-stranded RNA (dsRNA) can also be released. Collective release of these molecules triggers
inflammation via MAVS, cGAS-STING and NF-jB. Caspase activity is anti-inflammatory, in part, through direct cleavage and inactivation of inflammatory signalling
molecules.
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transformation [75]. A recent report by Brokatsky et al reveals a
link between pathogen invasion and activation of mitochondrial cell
death machinery [76]. In this study, it was found that various patho-
gens can induce limited mitochondrial permeabilisation. It remains
unclear how pathogens can trigger minority MOMP, but neverthe-
less they can, resulting in mtDNA release (presumably through
BAX/BAK pores), stimulating cGAS-STING activation and cytokine
secretion [76].
How else might mtDNA be released from mitochondria? Another
potential mechanism for mtDNA release from mitochondria is
through the mitochondrial permeability transition pore (mPTP)
[77,78]. The exact composition of the pore is unclear, although
there seems to be consensus that cyclophilin D is present [79]. The
mPTP spans the mitochondrial inner membrane and forms in
response to high mitochondrial calcium concentration and various
other cellular stresses. However, the mPTP is predicted to only
allow the efflux of molecules smaller than 1.5 kDa, much smaller
than a mtDNA nucleoid [80,81]. In line with this, studies have
shown that only fragments of mtDNA can pass through the mPTP
[77,82,83]. It remains possible that sustained opening of the pore
can lead to swelling of the mitochondria and subsequent rupture of
the inner membrane, which would permit the efflux of mtDNA into
the cytoplasm. The involvement of mPTP in mtDNA release during
cell death has been ruled out [61], but chitosan, a vaccine adjuvant,
appears to induce a cGAS-STING- and mPTP-dependent type I inter-
feron response. This is possibly due to mtDNA release, though a
direct role for mtDNA has not been rigorously assessed [84]. An
intriguing recent report suggests that cells experiencing mitochon-
drial stress caused by the lack of mitochondrial endonuclease G
release mtDNA through pores formed by oligomers of the voltage-
dependent anion channel (VDAC) [85]. As mitochondrial DNA
release is thought to play a role in the pathogenesis of lupus
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Figure 4. Non-cell autonomous effects of mtDNA.
(A) Upon pathogen encounter, neutrophils can extrude DNA (both nuclear and mitochondrial) that forms an extracellular trap for extracellular microbes. Due to pro-
inflammatory properties, these DNA neutrophil extracellular traps (NETs) can also have pathological effects in diseases such as lupus. (B) mtDNA can transfer via exosomes
or in intact mitochondria to neighbouring cells, impacting on the metabolism and survival of the recipient cell. Inflammatory responses to mtDNA can also have non-cell
autonomous effects. The cGAS-induced secondary messenger cGAMP has been shown to transfer via gap junctions eliciting anti-viral interferon responses in neighbouring
cells.
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[86,87], a role for VDAC pore formation was tested in an in vivo
model of lupus-like disease. Using the VDAC1 oligomerisation inhi-
bitor VBIT-4, the authors were able to reduce lupus-like symptoms
in lupus-prone mice, providing a rationale to target VDAC-mediated
mtDNA release in this disease [85].
Therapeutic targeting of mtDNA-dependent cGAS-STING activity
There is currently intense interest in the development of inhibitors
and activators of the cGAS-STING pathway, depending on the
disease. In humans, the systemic inflammatory disease Aicardi–
Goutie`res syndrome (AGS) is characterised by mutations in a
number of different genes involved in DNA sensing [88]. For exam-
ple, TREX1, a DNA exonuclease, is frequently mutated in human
patients with AGS and systemic lupus erythematosus (SLE) [89–91],
and co-deletion of cGAS, STING, Interferon-a/b receptor (IFNAR) or
IRF3 rescues this phenotype [92–98]. Accumulation of cytosolic
DNA appears to be a defining characteristic of AGS and SLE, as dele-
tions in DNA- and RNA-related genes including SAMDH1, a DNA
exonuclease and RnaseH2 are frequent [99–102]. Gain-of-function
mutations in STING itself lead to an up-regulation of type I inter-
feron responses and lupus-like symptoms in patients [103,104].
DNase II deficiency in humans leads to autoinflammation with
increased type I IFN [105] and in mice causes arthritis [106]. This is
thought to be due to the lack of self-DNA degradation in dead cells
engulfed by macrophages resulting in sustained cGAS-STING stimu-
lation [98,106,107], and AIM2 inflammasome formation [108,109]
with a possible contribution of endosomal TLRs [108]. Myocardial
infarction (MI) is another condition known to involve a strong
inflammatory component. King et al [110] showed that ischaemic
cell death and engulfment by macrophages drives an IRF3-depen-
dent type I IFN response. Genetic or pharmacological disruption of
cGAS-STING signalling in mice improved their outcomes post-MI,
proposing this signalling axis as suitable for therapeutic intervention
in patients [110,111]. While it is not clear if this is due to mtDNA
release per se, increased mtDNA in plasma from patients with heart
disease has been frequently observed [112–114]. Clearly, inhibiting
the cGAS-STING pathway in these disease settings might be benefi-
cial to patients. Small molecules targeting both cGAS [115,116] and
STING [117] have been developed, with STING antagonists emerg-
ing as the most promising. Blocking the IFNAR receptor to block
interferon signalling in SLE patients had seemed like a viable thera-
peutic route; however, late-stage clinical trials in this area have
failed, prompting more investigation of how important interferon
signalling is in the pathogenesis of SLE.
The ability to turn immunologically “cold” tumours “hot” and
make them more responsive to immunotherapy is a desirable
outcome in cancer treatment. Efficient T-cell responses to tumour
cells is a critical step to durable cancer treatment control [118].
STING is required for spontaneous CD8+ T-cell priming in vivo
[119]. Mechanistically, dying tumour cells transfer their DNA to
antigen-presenting dendritic cells when phagocytosed, eliciting
cGAS-STING-IRF3 signalling leading to an anti-tumour T-cell
response [119–121]. Activation of STING by addition of exogenous
cGAMP can also enhance anti-tumour immunity after irradiation
[120], the first evidence that therapeutic activation of STING may
improve cancer therapy. This effect was later shown to be exclusive
to dendritic cells over macrophages; blockade of the “don’t eat-me”
signal CD47 results in increased tumour-originated mtDNA in the
cytosol of DCs and is required for the cross-priming and type I IFN
response mediated through cGAS [122]. Dying tumour cells trans-
fected with exogenous cytosolic DNA, viral DNA or cyclic dinu-
cleotides (CDNs) have a greater capacity to activate STING
signalling in antigen-presenting cells, enhancing T-cell priming and
expansion of anti-tumour T cells [123]. Therefore, it is also possible
that mtDNA may act as a STING activator in antigen-presenting cells
(APCs) under certain circumstances, for example when apoptotic
caspases are inhibited. Another example of immune cell communi-
cation is in the interaction of T cells with antigen-presenting
dendritic cells. Upon formation of an immunological synapse
between these two cell types, T cells shed extracellular vesicles
(EVs) containing genomic and mtDNA. These EVs are taken up by
the dendritic cell, triggering a cGAS-STING-dependent anti-viral
response, conferring resistance to subsequent viral infection [124].
In the context of cancer treatment, it is plausible that apoptotic cell-
containing dendritic cells could stimulate a similar effect in T cells,
generating longer lived dendritic cells for more durable treatment
responses [125]. Together, these data and many others provide a
rationale for enhancing STING signalling in cancer treatment, and
this is currently under active investigation [126,127].
mtDNA release, cGAS-STING and neurodegeneration
Under normal, homeostatic conditions, damaged or stressed mito-
chondria are eliminated from the cell by a type of mitochondrial-
selective autophagy called mitophagy [128]. Mutations in proteins
involved in mitophagy pathways can contribute to neurodegenera-
tion. This is perhaps best evidenced for PINK1/Parkin-dependent
mitophagy. For instance, loss-of-function mutations in the PINK1/
Parkin pathway of mitophagy associate with early onset Parkinson’s
disease [129–133]. In a simplified view, the kinase PINK1 is acti-
vated on dysfunctional mitochondria where it phosphorylates ubiq-
uitin. Phospho-ubiquitin allosterically activates the E3 ubiquitin
ligase Parkin leading to enhanced mitochondrial ubiquitination that
serves as an autophagic signal to remove the damaged mitochon-
drion [134–136]. Parkinson’s disease is associated with neuroin-
flammation [137], and the serum from Parkinson’s patients is often
enriched for pro-inflammatory cytokines, including TNF, IL-1b, IFNɣ
and IL-6 [138,139]. However, many of the studies elucidating the
mechanistic basis of Parkinson’s have been performed in cultured
cell lines, and despite much effort, the in vivo relevance of PINK1/
Parkin-mediated mitophagy was not well understood, particularly
since mice that lack either PINK1 or Parkin exhibit no Parkinson’s-
like disease phenotypes [140–142]. Knowing that defective mito-
chondria can release innate immune-activating DAMPs, Sliter et al
[143] investigated the effect of exhaustive exercise or mtDNA muta-
tion on inflammation. When challenged with exhaustive exercise,
Parkin/ or Pink1/ mice displayed higher serum levels of pro-
inflammatory IL-6 and IFN-b when compared to wild-type mice, in
addition to increased levels of uncleared mitochondria. Remarkably,
this could be completely rescued by deletion of STING or administer-
ing IFNAR-blocking antibody to mice, strongly suggesting that
mtDNA released from damaged mitochondria that are not cleared is
responsible for the inflammation observed in Parkinson’s patients.
Interestingly, the authors also observed increased circulating mtDNA
in Parkin/ mice following exhaustive exercise, meaning that the
mtDNA is not only extruded from mitochondria but also exits the
cell. Mutator mice expressing a proofreading-defective mtDNA
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polymerase (PolG) accumulate mutations in mtDNA, which instead
of causing neurodegeneration results in dopaminergic neuron loss
and defective movement. While no difference in inflammatory cyto-
kine levels was noted between wild-type, Parkin/ or mutator mice,
Parkin/;mutator mice do have higher serum cytokine levels.
Again, cytokine levels and the movement disorder could be comple-
tely rescued by co-deletion of STING, reinforcing the cGAS-STING
axis as the major player in Parkinson’s-associated inflammation.
However, further work is needed to elucidate the absolute require-
ment for mtDNA over nuclear DNA and the precise mechanism of
how mtDNA is released from the mitochondria.
mtDNA as an inflammasome activator
Inflammasomes are multi-subunit complexes which form in
response to exogenous PAMPs and DAMPs [144]. One of four recep-
tors—absent in melanoma 2 (AIM2), NOD, LRR and Pyrin
domain-containing protein 1 (NLRP1), NLRP3 or NLR family CARD
domain-containing protein 4 (NLRC4), bind to the adaptor molecule
ASC forming a platform for the dimerisation, autoprocessing and
activation of caspase-1. Active caspase-1 can then process pro-IL-1b
and pro-IL-18 into their mature form so they can be secreted (see
Fig 1). The first report of mtDNA acting as an activator of inflamma-
somes came in 2011 when Nakahira et al [145] reported that deple-
tion of proteins involved in autophagy leads to an accumulation of
dysfunctional, persistent mitochondria exhibiting excessive ROS.
These mitochondria were more prone to extrude mtDNA into the
cytoplasm upon stimulation with lipopolysaccharide (LPS) or ATP,
dependent on the ability to from NLRP3 inflammasomes. Interest-
ingly, Nakahira et al suggested that as well as acting downstream of
mtDNA release, NLRP3 also acts upstream, to facilitate mPTP
formation on the mitochondria allowing mtDNA release. However,
as already discussed, whether mPTP is sufficient to allow mtDNA
translocation from the mitochondrial matrix into the cytoplasm is
debatable. Extending this work, the following year Shimada et al
[146] reported that during macrophage apoptosis mtDNA is released
and binds NLRP3. Notably, NLRP3 appears to have a preference for
oxidised mtDNA, clarifying the observations that ROS plays a
crucial role in inflammasome activation [147]. Linking these obser-
vations, deletion of the autophagy receptor p62 prevents mitophagic
clearance of mitochondria damaged by NLRP3 agonists, exacerbat-
ing inflammasome formation and IL-1b secretion [148]. More recent
work has pointed to newly synthesised, oxidised mtDNA as the
species which binds NLRP3 [149]. Zhong et al discovered that levels
of the mitochondrial deoxyribonucleotide kinase CMPK2 increase
upon LPS stimulation. CMPK2 catalyses a step in the synthesis of
the nucleotide cytidine triphosphate, which is rate-limiting for
mtDNA synthesis. Elevated dCTP levels in turn increase mtDNA
replication, which is oxidised by ROS and released into the cyto-
plasm where it can activate NLRP3 and stimulate IL-1b secretion.
However, the role of NLRP3 as a direct sensor of DNA is conten-
tious, as many disparate signals have been reported as the common
signal for NLRP3 activation [144]. Indeed, recent work from the
Chen laboratory has shown that dispersal of the trans-Golgi network
following K+ efflux is the likely common trigger [150].
Supporting the notion that inflammasomes and caspase activity
can act upstream of mtDNA release, there are reports that caspases
cause mitochondrial damage. For example, inflammasome-activated
caspase-1 has been reported to damage mitochondria and promote
the release of cytochrome c, indicative of mitochondrial outer
membrane permeabilisation [151]. The authors suggest that this is
due to mPTP formation, although a role for BAX and BAK was not
rigorously assessed in this work. Impairment of mitophagy was also
implicated, as Parkin was found to be a substrate of caspase-1 in
macrophages, leading to an accumulation of damaged, ROS-produ-
cing macrophages [151]. Furthermore, during infection-related ER
stress, NLRP3 (but not the adaptor protein ASC or caspase-1) is
involved in caspase-2 activation and cleavage of the pro-apoptotic
protein BID, promoting mitochondrial permeabilisation [152].
Neutrophil extracellular traps
So far, we have mainly discussed the cell autonomous role of
mtDNA release; however, it is becoming clear that mtDNA can also
be extruded from the mitochondria, into the cytoplasm and outward
further into the extracellular space. One interesting example of this
is in the generation of neutrophil extracellular traps, and in particu-
lar the role of mtDNA in their formation (Fig 4).
Neutrophils are the first line of attack in infection, capable of
engulfing pathogens and degranulating, the process of releasing
soluble anti-microbials. In 2004, Brinkmann and colleagues discov-
ered that upon stimulation with IL-8, phorbol myristate acetate
(PMA) or LPS, neutrophils extruded vast fibrous networks, which
they termed neutrophil extracellular traps (NETs) [153]. Analysis
of these NETs showed that they contained a variety of microbial-
killing proteins, including elastase, cathepsin G and myeloperoxi-
dase. However, they also contain DNA, as noted by reactivity with
antibodies against histones and DNA intercalating dyes. Successive
work showed that NETs were also enriched for mtDNA [154–156].
NET formation has been well studied in patients with systemic
lupus erythematosus (SLE), an autoimmune condition hallmarked
by the appearance of autoantibodies against dsDNA and RNA-
protein complexes, resulting in elevated type I interferon
responses. A number of studies show that mtDNA is part of NETs
formed in SLE. Caielli et al [87] found that in healthy neutrophils,
mitochondria with oxidative damage are removed not via mito-
phagy, but by extruding their mitochondrial matrix contents,
including TFAM-mtDNA nucleoids, into the extracellular space.
These TFAM-mtDNA nucleoids are devoid of oxidised DNA, and
so do not activate plasmacytoid dendritic cells (pDCs) and thus are
not immunogenic. Healthy neutrophils remove oxidised mtDNA by
signalling PKA phosphorylation of TFAM which initiates its degra-
dation and by shuttling oxidised mtDNA into lysosomes. In
contrast, neutrophils in SLE have reduced PKA activation and so
do not degrade TFAM as efficiently, leading to the extrusion of
immunogenic oxidised mtDNA [87]. Another report reveals ROS to
be an important mediator for neutrophils to produce oxidised
mtDNA-containing NETs in response to stimulation by ribonu-
cleotide immune complexes (RNP ICs) [86]. The authors also
found that injecting this DNA was pro-inflammatory and depen-
dent on the STING pathway revealing a dual role for mitochondria
in providing the source of DNA for NETs and oxidising it for maxi-
mal interferogenic response in SLE [86] (Fig 4). Sustained IFNa
signalling in SLE is also known to deregulate mitochondrial
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metabolism in monocytes, leading to reduced autophagy and an
accumulation of mtDNA in the cytoplasm. This leads to cGAS-
STING activation which promotes secretion of TNF and IL-6 and
the expansion of self-DNA autoreactive lymphocytes [157]. It is
now also appreciated that other cell types, including lymphocytes
and eosinophils, can secrete mtDNA-containing webs which act to
prime type I interferon responses in peripheral blood mononuclear
cells [158,159].
Nuclear DNA is prepared for expulsion as NETs through a highly
regulated process involving decondensation of chromatin and citrul-
lination of histones. Furthermore, plasma membrane permeabilisa-
tion is also regulated, inevitably leading to cell death. Within
minutes of stimulation, neutrophils rapidly produce NETs, whereas
the death of neutrophils (dubbed “NETosis”) occurs ~2 h after
[160]. While these two phenomena are often conflated in the litera-
ture, the timing argues against a general lytic mechanism of mtDNA
release. In fact, release of mtDNA as NETs seems to be energy-
dependent [161]. The precise mechanism of mtDNA escape during
NET formation remains to be elucidated; one possibility is that it
may be due to BAX/BAK pore formation on the mitochondrial outer
membrane [61,62], although this seems unlikely as this would
induce a rapid cell death.
mtDNA and TLR9
The Toll-like family of receptors (TLR) recognise a plethora of dif-
ferent bacterial features to instigate innate immunity. TLR9 recog-
nises hypomethylated CpG motifs found in bacteria. TLR9 is
expressed primarily in monocytes, macrophages, plasmocytoid
dendritic cells and B lymphocytes. In resting cells, TLR9 resides on
the endoplasmic reticulum, but recognition of DNA occurs in the
endolysosomes (see Fig 1) [162–165]. DNA-bound TLR9 recruits
MyD88 which activates MAPK and NF-jB, inducing an inflamma-
tory response. In common with bacterial DNA, mtDNA is
hypomethylated at CpG motifs, making it a potent activator of
TLR9 [166,167]. mtDNA detection by TLR9 was first noted in 2010
by Zhang et al, who observed that during systemic inflammatory
response syndrome (SIRS) mtDNA was released into the blood
where it can activate TLR9 on neutrophils [168,169]. In the heart,
autophagy is required to remove damaged mitochondria and main-
tain heart function during hemodynamic stress [170]. However,
when DNase II, a lysosomal DNase, is deleted from cardiac cells,
the mice succumb faster following heart pressure overload [171].
Delving deeper into the mechanism, the authors found that this
was due to an increase in mtDNA which has escaped degradation,
thus activating a TLR9-dependent inflammatory response [171].
Mitochondrial DNA released from dying cells or as part of NETs
can form a complex with the anti-microbial peptide LL-37. This
mtDNA:LL-37 complex evades degradation by DNase II and can
activate TLR9 on pDCs, neutrophils and endothelial cells to exacer-
bate atherosclerosis [172]. High-mobility group box 1 (HMGB1) is
a DNA-binding protein released from necrotic [173] and cytokine-
stimulated cells [174]. HMBG1 binds a receptor, called RAGE, lead-
ing to inflammatory signalling. In particular, HMGB1 has been
shown to be released from pDCs following stimulation with CpG
oligodeoxynucleotides (ODNs). CpG-ODNs can bind and activate
TLR9, but when complexed with HMGB1 the inflammatory
response is augmented through HMGB1 activation of RAGE [175].
In an analogous manner, TFAM co-operates with mtDNA released
from necrotic cells to increase pro-inflammatory signalling in pDCs
through RAGE and TLR9 [176,177].
TLR9 has been particularly well studied in liver pathologies. In
liver cancer, hypoxia triggers the translocation of mtDNA and
HMGB1 into the cytoplasm of cancer cells to activate TLR9, result-
ing in tumour cell proliferation [178]. TLR9 is crucial for the devel-
opment of acetaminophen-induced hepatotoxicity [179] and
fibrosis [180]. Development of non-alcoholic steatohepatitis
(NASH) involves innate immunity, with hepatic stellate cells and
macrophage-like Kupffer cells being particularly relevant. Mice fed
a choline-deficient amino acid-defined diet develop NASH, whereas
TLR9/ mice do not, implicating TLR9 as a requirement for
NASH development [181]. The precise ligand for TLR9-derived
liver disease was poorly understood, although the observation that
NASH patients had higher mitochondrial mass, but reduced respi-
ration, suggested that mitochondria may play a role [182]. In line
with these observations, Garcia-Martinez et al [183] found that
mice and human patients with NASH exhibited higher levels of
oxidised mtDNA in hepatocytes and plasma. As the oxidisation of
mtDNA increases its ability to activate TLR9, the authors con-
firmed that was the case. Importantly, mice dosed with a TLR9
antagonist displayed reduced symptoms of NASH, validating the
importance of mtDNA release and TLR9 signalling in the pathogen-
esis of NASH [183]. NASH is characterised by different forms of
cell death, most prominently apoptosis [184] and necrosis
[185,186]. In hepatocytes, mitochondrial permeabilisation results
in an increase of DNase II activity, and knockdown of DNase II
switches the mode of cell death to a RIP1-dependent non-apoptotic
form [187]. Importantly, this is due to the release of mtDNA after
mitochondrial permeabilisation, which triggers TLR9 signalling and
subsequent IFNb secretion. In mice fed a high-fat diet, a model of
NASH, DNase II activity is diminished, providing a mechanistic
link as to how necrosis of hepatocytes can augment NASH symp-
toms in patients [187]. It is unclear why the release of mtDNA trig-
gers either cGAS-STING or TLR9 signalling in different studies;
however, it may be due to different cell types, length or oxidation
status of mtDNA, activity of DNA nucleases or different cellular
compartments.
Mutations in OPA1, a protein required for mitochondrial inner
membrane fusion and cristae formation, have been reported to
cause mtDNA instability [188–191]. Deletion of OPA1 in skeletal
muscle, a tissue with high metabolic demands, predictably results in
mitochondrial dysfunction, mtDNA stress and inflammation leading
to reduced growth and early death in mice [192,193]. Interestingly
however, OPA1 deletion leads to disruption of mitophagy due to
impaired autophagic flux resulting in higher levels of dysfunctional
mitochondria in these tissues [194]. When mtDNA localisation was
examined, following OPA1 deletion there is high co-localisation of
mtDNA and TLR9, implicating TLR9 as the driver of OPA1-deletion
inflammation [194].
Transfer of mtDNA between cells
So far, this Review has mainly focussed on the cell-intrinsic biologi-
cal effects of mtDNA release. However, it is possible that released
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mtDNA nucleoids could move from one cell to another, thus
“spreading” the inflammatory signal across a population of cells. It
is now well established that mitochondria, including mtDNA, can be
transferred between cells (Fig 4). A seminal study in 1989 was the
first to describe such a phenomena, where cells devoid of mtDNA
(q0 cells) and thus lacking respiratory competence could be repopu-
lated with mitochondria from other cell lines [195]. More recent
work has shown that following stroke, whole mitochondria can be
transferred from astrocytes to neurons, a process proven to be bene-
ficial to recovery [196]. In cancer models, q0 cells have delayed
tumour growth, likely due to defects in energy production. Horizon-
tal transfer of mitochondria from cells in the tumour microenviron-
ment restored respiration in q0 cells and instigated tumour growth
[197]. Horizontal transfer of mitochondria could occur through a
number of different mechanisms. Firstly, cancer cells can form
tunnelling nanotubes with cells in the tumour microenvironment,
through which cytoplasmic contents, including mitochondria, can
be transferred [198]. Tunnelling nanotubes form between endothe-
lial cells and cancer cells to transfer mitochondria, conferring
chemoresistance to the cancer cell [199] but also between early
apoptotic cells and healthy cells, where mitochondrial transfer can
reverse apoptosis [200]. Secondly, mtDNA has been proposed to be
packaged into extracellular vesicles (EVs). Specifically, cancer-asso-
ciated fibroblasts can package entire mitochondrial genomes into
EVs which then fuse with cancer cells to transfer mtDNA. Impor-
tantly, the size of these EVs, ~100 nm, is far below the size of a
mitochondria, so making it unlikely that an entire mitochondria is
transferred in this manner [201]. However, mtDNA nucleoids are
within these size constraints [21]. It is important to note that other
studies see transfer of entire mitochondria between cells, and so
whether these or just mtDNA genomes are transferred is controver-
sial [202]. Thirdly, mitochondria can be directly transferred between
cells through connexin 43 gap junctions, as had been seen between
bone marrow-derived stromal cells and pulmonary alveoli during
lung injury [203]. Interestingly, transplanting tumour or embryonic
stem cells into hosts with the same nuclear DNA background but
different mtDNA from allogenic mouse strains resulted in rejection
[204]. Mechanistically, this is dependent on MyD88, the adaptor
molecule required for TLR9 signalling, suggesting that TLR9 may be
the PRR in this situation [204]. However, whether or how mtDNA is
released from these cells is unknown, but it is clear that allogenic
mtDNA can trigger innate immune pathways. This hints at the
intriguing notion that inflammation could spread between cells via
detection of mtDNA, perhaps through connexin 43 gap junctions, in
a similar manner to the observation that cGAMP can transfer to acti-
vate STING in neighbouring cells [71] (Fig 4). Contrary to this is
data showing that cell-free mtDNA (for example, as seen in sepsis)
can actually suppress inflammation [205]. Increased serum concen-
tration of mtDNA is associated with a poorer outcome in sepsis
patients, and injection of mtDNA in mice suppresses the adaptive
immune response in a TLR9-dependent manner [205]. Immunosup-
pressive markers, such as an increase in PD-L1 expression in the
spleen, are seen in mice injected with mtDNA, which is reflective of
what is seen in sepsis patients [205]. Clearly, there is conflicting
data on the immunostimulatory or immunosuppressive role of cell-
free mtDNA, which may depend on pathophysiological context;
nevertheless, release of mtDNA appears to potently affect the
immune system.
Conclusions and future perspectives
Mitochondria are multi-faceted organelles orchestrating key events
in both life and death. They represent a rich source of DAMPs which
can potently trigger the innate immune system, such as ATP, formyl
peptides and mtDNA. Possibly stemming from its bacterial origin,
mtDNA is particularly effective at initiating inflammatory and anti-
viral signalling.
The last number of years has seen an explosion in interest in
how mitochondria initiate innate immunity in the context of
pathogen invasion, cell death and pathology. However, many of
these studies leave us with unresolved questions as to precisely
how mtDNA is extruded from the mitochondria. In the context of
cell death, it is now clear that BAX and BAK form the pores on the
mitochondrial outer membrane through which the inner membrane
herniates, leading to mtDNA release, although how the inner
membrane permeabilises is as yet not fully resolved [61,62]. Many
other studies have suggested that the mPTP is involved in various
contexts, but again this is controversial. Clearly, further investiga-
tion is required, whether to determine a more universal role for
BAX/BAK-dependent mtDNA release, utilising our current knowl-
edge of the nature of the mPTP, or whether an altogether unknown
mechanism is involved.
It is also apparent that cellular context will determine how
mtDNA causes inflammation. cGAS-STING signalling seems to be
widely available across most cell types, a notable exception being
some transformed cells. However, TLR9 protein expression
appears to be restricted to immune cells, as does expression of
inflammasome components. Perhaps most interesting will be
determining what the outcomes of triggering innate immunity
with cytosolic or cell-free mtDNA are. For example, in the context
of cell death, does production of cGAMP in apoptotic cells transfer
to healthy apoptotic cells via gap junctions to promote a death-
resistant state, in a manner similar to what has been observed in
astrocytes [71]? Pathogen invasion stimulates a limited degree of
mtDNA release by hijacking the apoptotic machinery, so it is plau-
sible to see how this might act as a cell-intrinsic warning system,
but it will be fascinating to understand how this functions in the
context of a whole tissue. Furthermore, can we leverage what we
have learnt about anti-viral signalling during cell death to enhance
anti-cancer therapy by inhibiting caspases? Likewise, will our
understanding of how mtDNA and STING function in neurodegen-
eration lead to novel therapeutic strategies to enhance healthy
ageing [143]? Along these lines, mitochondrial dysfunction has
been shown to induce a specific form of senescence termed MiDAS
(mitochondrial dysfunction-associated senescence) [206]—given
the links between ageing, senescence and inflammation, it is
tempting to hypothesise that mtDNA plays a role in the initiation
of this phenotype.
A broad spectrum of pathologies, from cancer, to autoimmunity
and ageing all have aberrant mtDNA release as a driver or contribu-
tor of disease. Future work aimed at understanding how mtDNA is
involved will no doubt afford us new therapeutic avenues with
which to treat patients.
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In need of answers
(i) Why do different tissue and cell types respond to cytosolic mtDNA
through different pathways?
(ii) Can mtDNA release be harnessed therapeutically for treatment of
inflammatory diseases or cancer?
(iii) Where is cGAS located in the cell?
(iv) What are the physiological, non-lethal effects of mtDNA release
into the cytoplasm?
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